医药行业新闻-2024年8月1日

文章预览

1 Leveragen与Moderna达成合作，利用单域抗体技术推进新疗法 On July 30, 2024, Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered a multi-target research, option and license agreement with Moderna, Inc. Under the agreement, Leveragen will employ its proprietary fully human single domain antibody discovery platform to generate a panel of optimized binding modules against therapeutic targets selected by Moderna. Moderna will have the option to secure exclusive rights for the subsequent development and commercialization of the therapeutic products.During this partnership, Leveragen will spearhead the discovery of single domain antibody sequences for various targets. If Moderna decides to exercise its commercial option, it will be responsible for further development and commercialization efforts. Leveragen is set to receive an undisclosed upfront payment and researc ………………………………